top of page

Currently Recruitng

Clinical Trials

Currently Recruiting

3D Scans

Jazz Pharmaceuticals 406:

​

A Phase 3/4, An Open-Label, Multicenter, Switch Study Evaluating Changes in Blood Pressure in Participants with Narcolepsy Switching from High Sodium Oxybate to XYWAV

Jazz Pharmaceuticals 407:

​

A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low Sodium Oxybate Oral-Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy

Disclaimer About Medical Information
The medical information contained on this site is not intended or implied to be a substitute for professional medical advice, diagnosis, treatment, or as a replacement for medical advice offered by physicians. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only.  It should not be used or relied on for any diagnostic or treatment purposes, but rather patients and consumers should review the information carefully with their professional health care provider or physician. Neurocare, Inc. expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site.

Site Terms of Use

Legal

Notice of  Non-Discrimination

Neurocare, Center for Sleep

Corporate Headquarters

70 Wells Avenue, Newton MA 02459
ph. 617-796-7766
fax 617-796-9099

www.neurocareinc.com

​

​

© 2021 Neurocare, Inc.  All rights reserved.

HIPAA Privacy Practices

No Surprises

bottom of page